Reuters -- Roche’s (ROG.VX) top-selling drug MabThera has been recommended by Britain’s health cost agency for treating some patients with rheumatoid arthritis, in combination with the older drug methotrexate.
Reuters -- Roche’s (ROG.VX) top-selling drug MabThera has been recommended by Britain’s health cost agency for treating some patients with rheumatoid arthritis, in combination with the older drug methotrexate.